Redx Pharma to Be Acquired by Skye Bioscience, Concurrent $125 Million in Financings
Cooley advised Redx Pharma, a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, on its agreement to be acquired by Skye Bioscience, a clinical-stage biotechnology company. Upon completion of the transaction in accordance with the Transaction Agreement, the combined company will be led by Redx’s current management team and board of directors, plans to operate under the name Fibrx Therapeutics, Inc. (“Fibrx”), and trade on Nasdaq.
In connection with the transaction, Cooley also advised Redx Pharma on concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors.
The transaction was announced publicly in the following press release, which can be viewed here.
Rita Sobral, Russell Anderson, Claire Keast-Butler, Tom Goodman, Mark Jones, Ryan Genkin, Wouter Deelersnyder, Arthur Courroy and Philip Whitehead led the Cooley team advising Redx Pharma.
Bilal Ahmadzai, Susan Choy, David Wilson, Eerik Kukebal, Michael Bergmann, Jack Jones, Eileen Marshall, Sharon Davidov, Joe Sandys, Chris Lynn, Nicola Squire, Lyndsey Kruzer, and Alexandra Paterson provided invaluable support.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.